Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Achaogen (AKAO) and Acorda Therapeutics (ACOR).
Achaogen (AKAO)
In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Achaogen, with a price target of $2. The company’s shares closed yesterday at $0.86, close to its 52-week low of $0.86.
Arce said:
“916-3963, POS Risk-adj value Full value Rating ZEMDRI – U.S. 100% $1.35 $1.35 Shares outstanding 63,206 S/O: Post-Feb 2019 equity raise. ZEMDRI – EU 35% $0.35 $1.00 Current share price $0.86 Discount rate 24.0% C-Scape – U.S.”
According to TipRanks.com, Arce is a 4-star analyst with an average return of 8.5% and a 39.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Hold analyst consensus rating for Achaogen with a $3 average price target, a 249.3% upside from current levels. In a report issued on February 15, Mizuho Securities also maintained a Hold rating on the stock with a $3 price target.
See today’s analyst top recommended stocks >>
Acorda Therapeutics (ACOR)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Acorda Therapeutics today and set a price target of $33. The company’s shares closed yesterday at $13.10, close to its 52-week low of $12.86.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -12.3% and a 31.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Acorda Therapeutics has an analyst consensus of Hold, with a price target consensus of $21.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
